Successful strategies for treating type 1 diabetes need to restore the function of pancreatic
beta cells that are destroyed by the immune system and overcome further destruction of …

Autoimmune destruction of pancreatic beta cells in type I, insulin-dependent diabetes
mellitus (IDDM) results in the loss of endogenous insulin secretion, which is incompletely …

Rodent acinar cells exhibit a remarkable plasticity as they can transdifferentiate to duct-,
hepatocyte-and islet β-like cells. We evaluated whether exocrine cells from adult human …

Insulin-producing β cells are lost or insufficient in diabetic patients, presenting the medical
challenge for new β cells. Currently, there are three strategies that offer promise. One …

Diabetes mellitus, which affects more than 463 million people globally, is caused by the
autoimmune ablation or functional loss of insulin-producing β-cells, and prevalence is …

β-Cells derived from stem cells hold great promise for cell replacement therapy for diabetes.
Here we examine the ability of nuclear transfer embryonic stem cells (NT-ESs) derived from …

The treatment of diabetes mellitus represents one of the greatest medical challenges of our
era. Diabetes results from a deficiency or functional impairment of insulin-producing β cells …

A human pancreatic β-cell line that is functionally equivalent to primary β-cells has not been
available. We established a reversibly immortalized human β-cell clone (NAKT-15) by …

The discovery of insulin more than 90 years ago introduced a life‐saving treatment for
patients with type 1 diabetes, and since then, significant progress has been made in clinical …

Treatment of type 1 diabetes with insulin injection is expensive, complicated, and
insufficient. While cadaveric islet transplantations coupled with immunosuppressants can …